(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 10 Best and Safe Dividend Stocks to Buy Now. Bristol-Myers ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

E.U. says it'll buy $750 billion of U.S. energy products. Why that’s ‘absurd.' This was the stock's third consecutive day of ...

Our Bristol Myers Squibb Operating Income Comparison dashboard has more details. The company’s earnings stood at $2.97 on a per-share and reported basis in 2022, compared to the $2.02 figure in ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Princeton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, ...